35 mg given once weekly start on 2nd postoperative day for 26 weeks (6 months)

Placebo Comparator: Placebo

Drug: Placebo

Placebo given once weekly start on 2nd postoperative day for 26 weeks (6 months)

Detailed Description:

Periprosthetic bone loss after total hip arthroplasty is the main factor in limiting the longevity of implants used for treatment of osteoarthritis. Bone loss leads to implant destabilization. Bisphosphonates, given for approximately 6 months after THA man prevent this bone loss and lead to longer implant fixation and lower incidence of aseptic prosthesis loosening. We perform a clinical trial with risedronate to investigate if we can influence periprosthetic bone loss around a uncemented femoral stem.

Eligibility

Ages Eligible for Study:

40 Years to 70 Years

Genders Eligible for Study:

Both

Accepts Healthy Volunteers:

No

Criteria

Inclusion Criteria:

Patients on the waiting list for a total hip arthroplasty

Primary osteoarthritis

Osteoarthritis secondary to congenital dislocation of the hip

Exclusion Criteria:

Rheumatoid arthritis

Bisphosphonate treatment

Osteomalacia

Hypocalcemia

Previous surgery of the affected hip

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00772395